Scholarlink

Objective <p>This study aimed to preliminarily evaluate the value of <sup>18</sup>F-FAPI-04 PET/CT in assessing target lesions viability and treatment response in patients with unresectable hepatocellular carcinoma (uHCC) following Yttrium-90(<sup>90</sup>Y) microsphere selective internal radiation therapy (SIRT).</p> Methods <p>Patients with uHCC who underwent <sup>90</sup>Y-SIRT and subsequently received post-SIRT <sup>18</sup>F-FDG and/or <sup>18</sup>F-FAPI-04 PET/CT evaluations from February 2024 to June 2025 were retrospectively included. Visual assessments of post-SIRT target lesions were performed based on CECT/MRI, <sup>18</sup>F-FDG PET/CT, and <sup>18</sup>F-FAPI-04 PET/CT, and lesion detection efficacy was compared among the three methods. The SUV<sub>max</sub>, peak standardized uptake value corrected for lean body mass (SUL<sub>peak</sub>), metabolic/FAPI-avid tumor volumetric parameters of target and whole-body lesions before and after SIRT were measured, and the percentage changes (Δ%) were calculated. Post-SIRT response was assessed using mRECIST 1.1, <sup>18</sup>F-FDG, and <sup>18</sup>F-FAPI-04 PERCIST criteria.</p> Results <p>A total of 31 patients were included (mean age 51 ± 11, range: 38–75; males: 28). Post-SIRT <sup>18</sup>F-FAPI-04 PET/CT showed comparable sensitivity to CECT/MRI for both target and all intrahepatic lesions (target lesions: 95.2% vs. 81.0%, all intrahepatic lesions: 80.0% vs. 88.2%, both <i>P</i> &gt; 0.05), but lower specificity (target lesions: 64.3% vs. 100.0%, <i>P</i> = 0.063; intrahepatic lesions: 40.0% vs. 100.0%, <i>P</i> = 0.031). Compared with <sup>18</sup>F-FDG PET/CT, <sup>18</sup>F-FAPI-04 PET/CT had significantly higher sensitivity for detecting all intrahepatic lesions (78.9% vs. 55.3%, <i>P</i> = 0.023) but lower specificity (43.7% vs. 100.0%, <i>P</i> = 0.016). The concordance rates between <sup>18</sup>F-FDG PERCIST and mRECIST were 69.2% and 71.4% for target and whole-body lesions, respectively; between <sup>18</sup>F-FAPI-04 PERCIST and mRECIST, they were 73.3% and 75.0%, respectively. The mRECIST assessment results were significantly correlated with overall survival (OS), while <sup>18</sup>F-FAPI-04 PET/CT PERCIST indicated that progressive patients had worse OS. Post-SIRT lesion uptake, FAPI-avid tumor volumetric parameters on <sup>18</sup>F-FAPI-04 PET/CT, as well as ΔSUL<sub>peak</sub>-target%, may have prognostic value.</p> Conclusion <p>In uHCC patients undergoing <sup>90</sup>Y-SIRT,<sup>18</sup>F-FAPI-04 PET/CT shows high sensitivity but limited specificity for detecting post-SIRT intrahepatic lesions. Post-SIRT <sup>18</sup>F-FAPI-04 PET/CT parameters may carry prognostic value.</p> Trial registration <p>Chinese Clinical Trial Registry (ChiCTR2500107817), registered on 19 August 2025, retrospectively registered.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The value of 18F-FAPI-04 PET/CT in the assessment of unresectable hepatocellular carcinoma after selective internal radiation therapy: a preliminary exploratory study

  • 期刊论文

  • 发表日期：

    2026年5月23日

查看全文
  • Huanyu Gong,
  • Yong Cheng,
  • Zhilong Liu,
  • Kangshou Liu,
  • Yulong Liu,
  • Yingxin Li,
  • Jingjie Shang,
  • Bin Guo,
  • Qijun Cai,
  • Xueying Ling,
  • Chengzhi Li,
  • Mingrong Cao,
  • Lu Wang,
  • Jian Gong,
  • Hao Xu

摘要

Objective

This study aimed to preliminarily evaluate the value of 18F-FAPI-04 PET/CT in assessing target lesions viability and treatment response in patients with unresectable hepatocellular carcinoma (uHCC) following Yttrium-90(90Y) microsphere selective internal radiation therapy (SIRT).

Methods

Patients with uHCC who underwent 90Y-SIRT and subsequently received post-SIRT 18F-FDG and/or 18F-FAPI-04 PET/CT evaluations from February 2024 to June 2025 were retrospectively included. Visual assessments of post-SIRT target lesions were performed based on CECT/MRI, 18F-FDG PET/CT, and 18F-FAPI-04 PET/CT, and lesion detection efficacy was compared among the three methods. The SUVmax, peak standardized uptake value corrected for lean body mass (SULpeak), metabolic/FAPI-avid tumor volumetric parameters of target and whole-body lesions before and after SIRT were measured, and the percentage changes (Δ%) were calculated. Post-SIRT response was assessed using mRECIST 1.1, 18F-FDG, and 18F-FAPI-04 PERCIST criteria.

Results

A total of 31 patients were included (mean age 51 ± 11, range: 38–75; males: 28). Post-SIRT 18F-FAPI-04 PET/CT showed comparable sensitivity to CECT/MRI for both target and all intrahepatic lesions (target lesions: 95.2% vs. 81.0%, all intrahepatic lesions: 80.0% vs. 88.2%, both P > 0.05), but lower specificity (target lesions: 64.3% vs. 100.0%, P = 0.063; intrahepatic lesions: 40.0% vs. 100.0%, P = 0.031). Compared with 18F-FDG PET/CT, 18F-FAPI-04 PET/CT had significantly higher sensitivity for detecting all intrahepatic lesions (78.9% vs. 55.3%, P = 0.023) but lower specificity (43.7% vs. 100.0%, P = 0.016). The concordance rates between 18F-FDG PERCIST and mRECIST were 69.2% and 71.4% for target and whole-body lesions, respectively; between 18F-FAPI-04 PERCIST and mRECIST, they were 73.3% and 75.0%, respectively. The mRECIST assessment results were significantly correlated with overall survival (OS), while 18F-FAPI-04 PET/CT PERCIST indicated that progressive patients had worse OS. Post-SIRT lesion uptake, FAPI-avid tumor volumetric parameters on 18F-FAPI-04 PET/CT, as well as ΔSULpeak-target%, may have prognostic value.

Conclusion

In uHCC patients undergoing 90Y-SIRT,18F-FAPI-04 PET/CT shows high sensitivity but limited specificity for detecting post-SIRT intrahepatic lesions. Post-SIRT 18F-FAPI-04 PET/CT parameters may carry prognostic value.

Trial registration

Chinese Clinical Trial Registry (ChiCTR2500107817), registered on 19 August 2025, retrospectively registered.